跳至主要内容
临床试验/NCT00271076
NCT00271076已完成1 期

Carotid Artery Plaque Intravascular Ultrasound Evaluation

Arizona Heart Institute2 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2006年1月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
31
试验地点
2
主要终点
Primary endpoint: the completion of plaque morphology assessment & correlation of in-vitro histology with in-vivo histology using the Eagle Eye Gold Catheter.

研究概览

简要总结

To assess the safety and feasibility of Volcano Corp Eagle Eye Gold Catheter system to correlate the presence and characteristic of carotid artery atherosclerotic disease with anatomic and histologic analysis.

详细描述

A Phase , single center, prospective safety and feasibility study in patients diagnosed with carotid artery disease requiring intervention (carotid endarterectomy(CEA) or carotid artery stenting (CAS) with distal protection) as determined by the attending physician per standard treatment guidelines. At the time of the procedure, patients will undergo peri-operative assessment of their carotid artery disease with the study device.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • >18 years of age
  • Patient must be:
  • Symptomatic with lesions >/= to 50% stenosis, or Asymptomatic with lesions of >/= to 75% stenosis in at least one carotid artery, specific to the internal carotid artery, common carotid artery or bifurcated region; documented through acceptable ultrasound studies, completed within 30 days of recruitment.
  • For patients with bilateral carotid disease- procedures need to be staged greater than 30 days apart. The lesion that has a greater degree of stenosis will be considered as the index procedure.
  • Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment.
  • The patient is able to give informed consent.

排除标准

  • The patient is experiencing a new (acute) neurologic event or has experienced a stroke within the last 30 days prior to enrollment.
  • The patient has intracranial tumors, arterial vascular malformations >5mm, aneurysms or severe intracranial stenosis distal to the target lesion.
  • Presence of thrombus at the target site or loose 'floating' debris as determined by duplex analysis and/or angiography.
  • Existing hemorrhagic disease or coagulation problems creating inability to obtain homeostasis at entry site.
  • The patient has an allergy to, or is unable to tolerate, heparin, concomitant medications (clopidogrel or ticlid, aspirin) or to nitinol metal.
  • The patient has a history of or known reaction to radiocontrast agent (radiopaque dye) and is unable to be premedicated.
  • Coumadin treatment that has continued during the 48 hours prior to enrollment and an INR above hospital normals (i.e. in the event of atrial fibrillation or prosthetic valve replacement).
  • Hemodynamic instability at the time of intervention.
  • Severe chronic renal insufficiency (plasma/ serum creatinine> 2.5 mg/dL) at the time of intervention, except in patients on dialysis.

结局指标

主要结局

Primary endpoint: the completion of plaque morphology assessment & correlation of in-vitro histology with in-vivo histology using the Eagle Eye Gold Catheter.

次要结局

  • Secondary endpoint: safety and feasibility of the catheter system with respect to the possibility of assisting with the selection of a carotid stent, the relevance of pre-stent ballooning and ultimately the best treatment modality.

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验